Suppr超能文献

艾伯塔省行业资助的医疗器械临床试验成本。

The Costs of Industry-Sponsored Medical Device Clinical Trials in Alberta.

作者信息

Akpinar Ilke, Ohinmaa Arto, Thording Lars, Tran Dat T, Fedorak Richard N, Richer Lawrence, Jacobs Philip

机构信息

School of Public Health, University of Alberta, 3-267 Edmonton Clinic Health Academy, 11405-87 Ave, Edmonton, AB, T6G 1C9, Canada.

Innovative Health, Scottsdale, AZ, USA.

出版信息

Pharmacoecon Open. 2019 Dec;3(4):591-597. doi: 10.1007/s41669-019-0137-0.

Abstract

OBJECTIVE

Our objective was to describe the costs of industry-sponsored clinical trials for medical devices in Northern Alberta, Canada.

METHODS

We used centralized data to identify all industry-sponsored medical device clinical trials initiated in Northern Alberta from 2012 to 2016. For each arm of each trial, we calculated the price of devices provided by the sponsor and the cost of clinical and administrative services that were incurred to clinically operationalize the treatment.

RESULTS

Our sample consisted of 18 device trials initiated between January 2012 and January 2016. The overall cost (Canadian dollars [$Can], year 2018 values) per enrolee was $Can18,243 for the experimental arm and $Can13,827 for the control arm. Devices were the highest cost component, at $Can13,446 per enrollee in the experimental arm. Clinical costs in the control arms were higher on average ($Can7202 vs. 2504) than those in the experimental arms.

CONCLUSION

Data from industry-sponsored clinical trials can provide important information on the full costs of device-related interventions. As device costs rise, and as policy makers require more evidence on device-related treatments, the cost of medical device-driven interventions should be documented along with their effectiveness.

摘要

目的

我们的目的是描述加拿大艾伯塔省北部由行业资助的医疗器械临床试验成本。

方法

我们使用集中数据来识别2012年至2016年在艾伯塔省北部启动的所有由行业资助的医疗器械临床试验。对于每项试验的每个组,我们计算了赞助商提供的器械价格以及为使治疗临床实施而产生的临床和行政服务成本。

结果

我们的样本包括2012年1月至2016年1月期间启动的18项器械试验。试验组每位受试者的总成本(2018年加元价值)为18,243加元,对照组为13,827加元。器械是成本最高的组成部分,试验组每位受试者的器械成本为13,446加元。对照组的临床成本平均(7202加元对2504加元)高于试验组。

结论

行业资助的临床试验数据可以提供有关器械相关干预措施全部成本的重要信息。随着器械成本上升,以及政策制定者需要更多关于器械相关治疗的证据,医疗器械驱动的干预措施的成本应与其有效性一并记录。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0a3/6861404/0c7b2507f9a2/41669_2019_137_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验